Combining a GSI and BCL-2 inhibitor to overcome melanoma's resistance to current treatments-Reference-Cited by-同舟云学术

Combining a GSI and BCL-2 inhibitor to overcome melanoma's resistance to current treatments

Published:2016-11-05 Issue:51 Volume:7 Page:84594-84607
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Mukherjee Nabanita¹,Almeida Adam¹,Partyka Katie A.¹,Lu Yan¹,Schwan Josianna V.¹,Lambert Karoline¹,Rogers Madison¹,Robinson William A²,Robinson Steven E²,Applegate Allison J²,Amato Carol M²,Luo Yuchun¹,Fujita Mayumi¹,Norris David A.¹³,Shellman Yiqun G.¹

Affiliation:

1. University of Colorado Anschutz Medical Campus, School of Medicine, Department of Dermatology, Aurora, CO 80045, USA

2. Division of Medical Oncology, University of Colorado Anschutz Medical Campus, School of Medicine, Aurora, CO 80045, USA

3. Department of Veterans Affairs Medical Center, Dermatology Section, Denver, CO 80220, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug tolerant persister cell plasticity in cancer: a revolutionary strategy for more effective anticancer therapies;Signal Transduction and Targeted Therapy;2024-08-14

2. MCL1 inhibition targets Myeloid Derived Suppressors Cells, promotes antitumor immunity and enhances the efficacy of immune checkpoint blockade;Cell Death & Disease;2024-03-08

3. Uncovering NOTCH1 as a Promising Target in the Treatment of MLL-Rearranged Leukemia;International Journal of Molecular Sciences;2023-09-23

4. Therapeutic Targeting of Regulated Signaling Pathways of Non-Small Cell Lung Carcinoma;ACS Omega;2023-07-17

5. TRAIL in the Treatment of Cancer: From Soluble Cytokine to Nanosystems;Cancers;2022-10-19